- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax
- Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–81
of 81
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Lenalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Aurora, Colorado • Columbus, Ohio
- Conditions
- CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Subcutaneous Blinatumomab
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Leukemia, Myeloid Leukemia, Monocytic Leukemia
- Interventions
- Venetoclax, Azacitidine, Mitoxantrone
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Growth Hormone Deficiency
- Interventions
- Not listed
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- STAT Inhibitor OPB-111077, Decitabine, Venetoclax, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Trauma
- Interventions
- Flashback CRI T1 Tablet
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 26 Years
- Enrollment
- 300 participants
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia
- Conditions
- Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- San Carlos, California • Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukaemia (AML)
- Interventions
- Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey